237386-01-5

Usage

General Description

2-Bromo-1-(3-(trifluoromethoxy)phenyl)ethanone is a chemical compound with the formula C10H8BrF3O2. It is a synthetic intermediate used in the production of pharmaceuticals and other organic compounds. 2-BroMo-1-(3-(trifluoroMethoxy)phenyl)ethanone consists of a benzene ring with a trifluoromethoxy group attached to the third carbon, and an ethanone group attached to the first carbon. Its unique structure and functional groups make it a versatile reagent for various chemical processes, and it is commonly used in organic synthesis and medicinal chemistry.

Upstream product

• 170141-63-6 1-(3-trifluoromethoxy-phenyl)ethanone 

Downstream Products

• 956832-29-4 2-(2-amino-6-bromophenoxy)-1-(3-trifluoromethoxyphenyl)ethanone 
• 677713-02-9 3-oxo-3-(3-(trifluoromethoxy)phenyl)propanenitrile 
• 1198170-88-5 2-(3-(trifluoromethoxy)phenyl)imidazo[1,2-a]pyridine-8-carboxylic acid 
• 1198170-86-3 ethyl 2-(3-(trifluoromethoxy)phenyl)imidazo[1,2-a]pyridine-8-carboxylate 
• 1082949-82-3 2-azido-1-(3-(trifluoromethoxy)phenyl)ethanone 
• 1015756-72-5 C₁₂H₇F₃N₂OS 
• 254912-01-1 methyl 3-[4-(3-trifluoromethoxyphenyl)-2-thiazolyl]benzoate 
• 254911-16-5 methyl 4-[4-(3-trifluoromethoxyphenyl)-2-thiazolyl]benzoate 
• 684220-65-3 4-(3-trifluoromethoxyphenyl)imidazole 

Relevant academic research and scientific papers

N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS

The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibros

SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES

The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors

2,3-Dihydro-3,8-diphenylbenzo[1,4]oxazines were identified as a new class of potent cholesteryl ester transfer protein inhibitors. The most potent compound 6a (IC50 = 26 nM) possessed a favorable pharmacokinetic profile with good oral bioavailability in rat (F = 53%) and long human liver microsome stability (t1/2 = 62 min). It increased HDL-C in human CETP transgenic mice and high-fat fed hamsters. The structure and activity relationship of this series will be described in this Letter.

Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists

Leukocyte recruitment of sites of inflammation and tissue injury involves leukocyte rolling along the endothelial wall, followed by firm adherence of the leukocyte, and finally transmigration of the leukocyte across cell junctions into the underlying tissue. The initial rolling step is mediated by the interaction of leukocyte glycoproteins containing active moieties such as sialyl Lewisx (sLex) with P-selectin expressed on endothelial cells. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of inflammatory diseases such as arthritis. High-throughput screening of the Wyeth chemical library identified the quinoline salicylic acid class of compounds (1) as antagonists of P-selectin, with potency in in vitro and cell-based assays far superior to that of sLex. Through iterative medicinal chemistry, we identified analogues with improved P-selectin activity, decreased inhibition of dihydrooratate dehydrogenase, and acceptable CYP profiles. Lead compound 36 was efficacious in the rat AIA model of rheumatoid arthritis.

Pyrimidine derivatives as IL-8 receptor antagonists

Compounds containing the pyrimidine nucleus and their use to treat diseases and conditions related to inappropriate Interleukin-8 receptor activity are disclosed. The compounds are of the formula I In these compounds, Q is preferably unsubstituted and substituted heterocyclyl; U is usually hydrogen or fluorine; and V is preferably hydrogen, halogen, alkyl, —O—alkyl or —S-alkyl. A representative example is:

(2S)-2-((PYRIMIDIN-4-YL)AMINO)-4-METHYLPENTANOIC ACID AMINOETHYLAMID DERIVATIVES AS IL-8 RECEPTOR MODULATORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS

The invention relates to compounds of the formula: (I); wherein R1 is a basic moiety having the structure -NH(CH2)2NR5R6, (Formula II) or (Formula II); wherein R5, R6 and R7 are independently selected from H, (1-6C)alkyl, (2-6C)alken

Diaminothiazoles having antiproliferative activity

Disclosed are novel diaminothiazoles that are selective inhibitors of Cdk4. These compounds and their pharmaceutically acceptable salts and esters are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing these compounds as well as intermediates useful in the preparation of the compounds.